QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How the EU Centralised Marketing Authorisation Procedure Works

Test your understanding of the concepts covered by How the EU Centralised Marketing Authorisation Procedure Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 For a centralised application for a human medicinal product, which body has the principal role in adopting the scientific opinion?

PRAC CAT in every case CHMP The European Commission

Question 2 of 10 An application passes validation but later receives substantial questions about efficacy and safety. What does this demonstrate?

Validation is a preliminary scientific approval Validation confirms only that the application is sufficiently compliant and complete for the formal scientific procedure to proceed The later questions indicate that the validation decision was invalid A validated application cannot receive additional questions

Question 3 of 10 Which statement most accurately distinguishes EMA, CHMP and the European Commission in the centralised procedure?

EMA adopts the legally binding authorisation after CHMP provides administrative support CHMP grants the marketing authorisation and the Commission performs scientific assessment EMA coordinates and supports the process, CHMP adopts the scientific opinion, and the Commission adopts the legally binding decision The European Commission coordinates the scientific assessment while EMA adopts the final opinion

Question 4 of 10 Which applicant practice is most important when preparing responses to regulatory questions?

Address only the question that appears most likely to affect the opinion Provide a general narrative response and leave cross-dossier updates until after approval Map each question to supporting evidence, explain the reasoning and maintain consistency across the dossier and product information Avoid proposing changes because assessors cannot consider amendments during assessment

Question 5 of 10 What does technical validation primarily examine?

Whether the product has a favourable benefit-risk balance Whether the clinical evidence proves efficacy for the proposed indication Whether the electronic submission is structurally and technically compliant Whether the Commission should grant the marketing authorisation

Question 6 of 10 What is the most appropriate interpretation of a List of Questions (LoQ)?

It is the final legal decision on the application It is a scientific and regulatory request for clarification, additional analysis, justification or related changes during assessment It is limited to missing administrative forms It proves that CHMP has already decided to issue a negative opinion

Question 7 of 10 Which statement best reflects the integrated assessment of quality, efficacy and safety?

Each discipline produces an independent pass or fail result that is simply added together Only efficacy determines the benefit-risk balance once quality requirements are met Findings in one domain can change the interpretation or regulatory significance of findings in another domain Safety and risk management are considered only after the Commission decision

Question 8 of 10 Why should the standard 210-day assessment framework not be treated as a fixed 210-calendar-day period from submission to opinion?

The 210 days refer only to the period before submission The framework measures active assessment time and excludes applicable clock stops while the applicant responds The Commission may always extend the period without procedural basis The period includes only time spent on manufacturing inspections

Question 9 of 10 Which situation most appropriately supports consideration of accelerated assessment?

The applicant wants an earlier decision for commercial reasons The product is of major public-health interest and the applicant provides the required justification under the applicable criteria The dossier is incomplete but the applicant promises to provide data later The product has already been authorised in one Member State

Question 10 of 10 What is the key regulatory distinction between accelerated assessment and a reduced evidentiary standard?

Accelerated assessment shortens active assessment time but does not lower the evidence requirements Accelerated assessment removes the need for a risk-management plan Accelerated assessment permits approval based on preliminary evidence alone Accelerated assessment replaces CHMP assessment with EMA administrative review

QPPV.com

Knowledge Assessment: How the EU Centralised Marketing Authorisation Procedure Works

Cookie Settings